{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Initial-EC-IRB-Submission-and-Approval-Tracking”
},
“headline”: “SOP for Initial Ethics Committee and IRB Submission with Approval Tracking”,
“description”: “This SOP provides a regulatory-compliant framework for initial submissions to Ethics Committees/IRBs and for maintaining approval tracking, aligned with ICH GCP, WHO, FDA, EMA, and CDSCO requirements.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Initial EC/IRB Submission and Approval Tracking in Clinical Trials

Purpose

The purpose of this SOP is to provide standardized instructions for preparing, submitting, and tracking initial applications to Ethics Committees (EC) or Institutional Review Boards (IRB) for clinical trials. This ensures compliance with ICH-GCP, WHO, FDA, EMA, and CDSCO requirements while safeguarding the rights, safety, and well-being of trial participants.

Scope

This SOP applies to all clinical trial staff, investigators, regulatory affairs teams, and quality assurance personnel responsible for submitting trial protocols and related documents to EC/IRBs for initial review and approval before trial initiation.

Responsibilities

• Principal Investigator (PI): Prepares the submission package including protocol, informed consent forms, and investigator’s brochure.
• Regulatory Affairs Manager: Coordinates submission and ensures compliance with local and international regulations.
• Clinical Research Associate (CRA): Supports documentation and follows up with EC/IRB on submission status.
• Quality Assurance Officer: Reviews the package for completeness and regulatory compliance.
• Head of Clinical Research: Approves the final submission package prior to dispatch.

Accountability

The Regulatory Affairs Head is accountable for ensuring timely submission and approval tracking of EC/IRB applications. Any delays or errors may result in trial initiation delays or non-compliance findings during inspections.

Procedure

1. Preparation of Submission Package
Collect required documents: Clinical Trial Protocol, Investigator’s Brochure (IB), Informed Consent Form (ICF), Case Report Forms (CRFs), subject recruitment materials, and insurance certificates.
Ensure documents are in line with ICH-GCP and local regulations.
Prepare cover letter summarizing submission contents.

2. Internal Review and Approval
QA reviews submission package for accuracy and completeness.
Obtain approvals from PI and Head of Clinical Research.
Maintain version control for all documents submitted.

3. Submission to EC/IRB
Submit package electronically or in hard copy as per EC/IRB requirements.
Ensure acknowledgment receipt from EC/IRB is obtained and filed.

4. Approval Tracking
Record submission and approval dates in the EC/IRB Approval Tracker.
Follow up periodically with EC/IRB for review status.
File approval letters and conditions in the Trial Master File (TMF).

5. Communication and Implementation
Communicate approval status to sponsor and trial sites.
Implement EC/IRB requirements or conditions before trial initiation.

Abbreviations

• SOP: Standard Operating Procedure
• EC: Ethics Committee
• IRB: Institutional Review Board
• PI: Principal Investigator
• CRA: Clinical Research Associate
• QA: Quality Assurance
• IB: Investigator’s Brochure
• ICF: Informed Consent Form
• CRF: Case Report Form
• TMF: Trial Master File

Documents

1. Initial EC/IRB Submission Checklist (Annexure-1)
2. EC/IRB Approval Tracker (Annexure-2)
3. EC/IRB Communication Log (Annexure-3)

References

• ICH E6(R2) Good Clinical Practice
• US FDA 21 CFR Part 56 – Institutional Review Boards
• EMA Clinical Trial Regulation (EU No. 536/2014)
• WHO Operational Guidelines for Ethics Committees
• CDSCO Clinical Trial Rules, India (2019)

Version: 1.0

Approval Section

Annexures

Annexure-1: Initial EC/IRB Submission Checklist

Annexure-2: EC/IRB Approval Tracker

Annexure-3: EC/IRB Communication Log

Revision History

For more SOPs visit: Pharma SOP

One of the most critical components of clinical study start-up is the preparation and coordination of regulatory submissions and Institutional Review Board (IRB) approvals. A smooth regulatory process ensures ethical compliance, protects subjects, and prevents study delays. This tutorial outlines best practices, timelines, and responsibilities in regulatory submission and IRB coordination.

What Are Regulatory Submissions and Why Are They Critical?

Regulatory submissions are formal communications to competent authorities and ethics committees seeking permission to conduct a clinical trial. These include applications, notifications, and approvals for drugs, devices, or biologics.

• Ensure compliance with USFDA, CDSCO, EMA, or other regional authorities
• Protect patient rights and trial integrity
• Fulfill GCP obligations and avoid protocol deviations

Core Documents Required for Regulatory and IRB Submissions:

Clinical trial submissions typically include:

1. Final Protocol with Version History
2. Investigator’s Brochure (IB)
3. Informed Consent Form (ICF)
4. Patient Information Sheet (PIS)
5. CVs and Licensure of Investigators
6. Site-Specific Information and SOPs
7. Insurance Certificate
8. Study Budget and Contract Summary
9. Regulatory Forms (e.g., FDA Form 1572 or equivalent)

Additional country-specific documents may be required based on regulatory jurisdiction.

Steps in Preparing a Regulatory Submission:

Follow these steps to ensure completeness and accuracy in submission:

1. Create a submission dossier aligned with ICH and local requirements
2. Use a document checklist and pre-review template for QC
3. Validate translations for non-English countries
4. Convert and label all PDFs for e-submission (if applicable)
5. Include a cover letter with trial summary and investigator details

For template management and SOP controls, refer to systems like Pharma SOP documentation.

IRB/EC Coordination Process Explained:

Institutional Review Boards (IRBs) or Ethics Committees (ECs) independently review clinical trials to ensure participant safety and ethical integrity. Coordinating with them involves:

• Identifying IRB submission windows and deadlines
• Preparing submission packets with full study materials
• Filing digital or hardcopy submissions based on IRB requirements
• Monitoring status and responding to queries

Submission Timelines and What to Expect:

Timelines vary but typically follow this structure:

• IRB Initial Review: 3–6 weeks
• Regulatory Authority Review (e.g., CDSCO): 30–90 days
• Clarification Requests/Resubmissions: Additional 2–4 weeks
• Final Approval: Must be documented and dated

Tracking tools and calendars are essential for managing these timelines across sites.

Country-Specific Considerations:

Regulatory processes differ between countries. For instance:

• In India, both CDSCO and Institutional Ethics Committees must approve
• In the US, an IND application is required before trial start
• EU trials must follow EMA’s Clinical Trials Regulation (CTR)

Always consult local regulations and ethics guidelines to ensure full compliance.

Communication Logs and Documentation:

Clear documentation of all IRB and regulatory communications is critical. Maintain logs for:

• Submission Dates and Versions
• Approval Letters with Stamps and Signatures
• Emails and Meeting Notes
• Queries Raised and Responses Provided

This practice aligns with audit readiness and GMP documentation standards.

Common Mistakes to Avoid:

Errors in submission coordination can lead to delays or rejection. Avoid the following:

• Submitting outdated protocol or consent forms
• Missing investigator signatures on forms
• Inconsistent site-specific details across documents
• Late responses to IRB/authority queries

Best Practices for Seamless IRB and Regulatory Management:

1. Develop a submission checklist customized to country and sponsor
2. Establish regular follow-up calls with IRB contacts
3. Use e-submission platforms where available (e.g., SUGAM portal in India)
4. Assign submission tasks with defined roles and timelines
5. Keep a centralized repository for all approvals and communications

Post-Approval Requirements and Ongoing Coordination:

Regulatory submission doesn’t end with approval. Maintain compliance through:

• Timely submission of protocol amendments
• Safety reports and periodic updates (e.g., DSURs)
• Re-consenting if changes impact participant information
• Regular submission of progress and closeout reports

Conclusion:

Regulatory submissions and IRB coordination are foundational to clinical trial execution. With the right SOPs, submission tools, and communication practices, sponsors and sites can avoid delays and maintain full compliance. Utilize centralized templates, ethical frameworks, and timely communication to manage this critical part of the study start-up lifecycle. For more guidance on ethical submissions, visit Stability Studies.